Kai-Chen Wu
Overview
Explore the profile of Kai-Chen Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Poon E, Liu L, Wu K, Lim J, Sweet M, Lohman R, et al.
Br J Pharmacol
. 2024 Sep;
181(23):4804-4821.
PMID: 39223784
Background And Purpose: Most inhibitors of histone deacetylases (HDACs) are not selective and are cytotoxic. Some have anti-inflammatory activity in disease models, but cytotoxicity prevents long-term uses in non-fatal diseases....
2.
Triantafyllos Gerokonstantis D, Mantzourani C, Gkikas D, Wu K, Hoang H, Triandafillidi I, et al.
J Med Chem
. 2023 Oct;
66(20):14357-14376.
PMID: 37795958
Inhibitors of histone deacetylases (HDACs) have received special attention as novel anticancer agents. Among various types of synthetic inhibitors, benzamides constitute an important class, and one is an approved drug...
3.
Wu K, Condon N, Hill T, Reid R, Fairlie D, Lim J
J Innate Immun
. 2023 Mar;
15(1):468-484.
PMID: 36882040
Complement activation and Rab GTPase trafficking are commonly observed in inflammatory responses. Recruitment of innate immune cells to sites of infection or injury and secretion of inflammatory chemokines are promoted...
4.
de Araujo A, Lim J, Wu K, Hoang H, Nguyen H, Fairlie D
RSC Chem Biol
. 2022 Jul;
3(7):895-904.
PMID: 35866171
Cyclic peptides that modulate protein-protein interactions can be valuable therapeutic candidates if they can be delivered intact to their target proteins in cells. Here we systematically compare the effects of...
5.
Mantzourani C, Gkikas D, Kokotos A, Nummela P, Theodoropoulou M, Wu K, et al.
Bioorg Chem
. 2021 Jul;
114:105132.
PMID: 34229198
Hydroxamic acid derivatives constitute an interesting novel class of antitumor agents. Three of them, including vorinostat, are approved drugs for the treatment of malignancies, while several others are currently under...
6.
Mak J, Wu K, Gupta P, Barbero S, McLaughlin M, Lucke A, et al.
J Med Chem
. 2021 Feb;
64(4):2186-2204.
PMID: 33570940
The zinc-containing histone deacetylase enzyme HDAC7 is emerging as an important regulator of immunometabolism and cancer. Here, we exploit a cavity in HDAC7, filled by Tyr303 in HDAC1, to derive...
7.
PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR
Jiang Y, Lim J, Wu K, Xu W, Suen J, Fairlie D
Br J Pharmacol
. 2020 Nov;
178(4):913-932.
PMID: 33226635
Background And Purpose: Specific cellular functions mediated by GPCRs are often associated with signalling through a particular G protein or β-arrestin. Here, we examine signalling through a GPCR, protease-activated receptor...
8.
Tng J, Lim J, Wu K, Lucke A, Xu W, Reid R, et al.
J Med Chem
. 2020 May;
63(11):5956-5971.
PMID: 32383881
AR-42 is an orally active inhibitor of histone deacetylases (HDACs) in clinical trials for multiple myeloma, leukemia, and lymphoma. It has few hydrogen bond donors and acceptors but is a...
9.
Rowley J, Reid R, Poon E, Wu K, Lim J, Lohman R, et al.
J Med Chem
. 2020 Jan;
63(2):529-541.
PMID: 31910011
Structure-activity relationships for a series of small-molecule thiophenes resulted in potent and selective antagonism of human Complement C3a receptor. The compounds are about 100-fold more potent than the most reported...
10.
de Araujo A, Lim J, Wu K, Xiang Y, Good A, Skerlj R, et al.
J Med Chem
. 2018 Mar;
61(7):2962-2972.
PMID: 29584430
A 26-residue peptide BimBH3 binds indiscriminately to multiple oncogenic Bcl2 proteins that regulate apoptosis of cancer cells. Specific inhibition of the BimBH3-Bcl2A1 protein-protein interaction was obtained in vitro and in...